Careers article - November 21, 2017
Amsterdam selected as new location for EMA
Late yesterday afternoon the General Affairs Council of the European Union decided that the European Medicines Agency (EMA) will relocate to Amsterdam when it leaves London in 2019. The vote had to be determined by drawing the name of the new city out of a hat at random, after a tie between Amsterdam and Milan in […]
Drug Development Pharma - November 13, 2017
New survey from SwedenBIO: What EMA personnel can expect of life in Stockholm
Due to the upcoming vote on where the new EMA office will be located SwedenBIO asked some of their international industry colleagues to share their personal experiences of what it is like to live and work in Sweden. On November 20th it is time for the EU ministers to decide and vote where the new […]
Collaboration - November 11, 2017
NeuroVive collaborates with Lund University
NeuroVive Pharmaceutical and Ramin Massoumi at Lund University have been granted 2,5 MSEK from the Swedish Foundation for Strategic Research (SFF) for an Industrial PhD to study the role of cyclophilins in liver cancer. The research will be done within NeuroVive’s project NVP024, which is focused on the development of a novel liver cancer treatment. The overall objective of […]
Drug Development Pharma - November 8, 2017
New cancer project for Medivir
Medivir announces a new discovery project for a cancer indication. The Leukotide project is intended to deliver a new drug for the treatment of acute myeloid leukemia (AML) and other hematological malignancies, and is based on the company’s expertise in nucleoside and nucleotide science. It represents the second cancer project to emerge from its in-house […]
Drug Development Pharma - November 7, 2017
Beactica makes new investments and appointments
Beactica announces the completion of its latest financing round and the appointments of Erik Walldén and Uli Hacksell to its Board, aiming to strengthen the company’s position in the developing of specialist oncology therapeutics. In addition, Dong-A ST Co., Ltd (170900: Korea SE), the Korean pharmaceutical company and one of Beactica’s collaborators, has become a […]
Drug Development Pharma - November 7, 2017
New Vice President of Oncology R&D at Orion
Professor Heikki Joensuu, M.D., Ph.D., has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation as of 1 December 2017. Heikki Joensuu (born 1956) is a Finnish oncologist and cancer researcher. Joensuu joins Orion from the Comprehensive Cancer Center, Helsinki University Hospital, where he worked as the Research Director from 2015 to 2017. […]
